For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Anaptysbio, Inc.

USPTO Granted Patents = 21

CIPO Patents = 1

EPO Patents = 5

Trademarks = 2

Forward Citations = 81

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

David J King (17 out of 53 patents)

Peter M Bowers (11 out of 11 patents)

Robert A Horlick (10 out of 15 patents)

4. Marilyn Kehry (7 out of 12 patents)

5. Andrew John McKnight (6 out of 7 patents)

6. Andrew B Cubitt (4 out of 19 patents)

7. Marco Londei (3 out of 3 patents)

8. Jean Da Silva Correia (2 out of 2 patents)

9. Baochuan Huang (2 out of 2 patents)

10. Tamlyn Yee Neben (2 out of 2 patents)

11. Xue Zhang (1 out of 6 patents)

12. Helen Toni Jun (1 out of 4 patents)

13. Jennifer Dalton (1 out of 1 patent)

14. Betty Wu (1 out of 1 patent)

15. Traci Roberts (1 out of 1 patent)

21 patents: Sort by Forward Citations

1. 12391761 - Antibodies directed against interleukin 36 receptor (IL-36R) (2025-08-19),

2. 11999783 - Method of treating autoimmune disease with antibodies against IL-33 (2024-06-04),

3. 11753472 - Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3) (2023-09-12),

4. 11352427 - Antibodies directed against T Cell immunoglobulin and mucin protein 3 (TIM-3) (2022-06-07),

5. 11155624 - Antibodies directed against programmed death-1 (PD-1) (2021-10-26),

6. 11130814 - Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (IL-36R) (2021-09-28),

7. 10836824 - Antibodies directed against lymphocyte activation gene 3 (LAG-3) (2020-11-17),

8. 10836820 - Method of treating inflammatory disorder with antibodies directed against interleukin-33 (IL-33) (2020-11-17),

9. 10738117 - Antibodies directed against programmed death-1 (PD-1) (2020-08-11),

10. 10526410 - Antibodies directed against interleukin 36 receptor (IL-36R) (2020-01-07),

11. 10508149 - Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3) (2019-12-17),

12. 10059764 - Antibodies directed against interleukin-33 (IL-33) and methods of making and using (2018-08-28),

13. 9951126 - Antibodies directed against nerve growth factor (NGF) (2018-04-24),

14. 9815897 - Antibodies directed against programmed death-1 (PD-1) (2017-11-14),

15. 9637556 - Methods of generating libraries and uses thereof (2017-05-02),

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of antibody-based therapeutics to address unmet medical needs in inflammation and immuno-oncology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

21 Patents

#271 in San Diego, CA

#3,627 in California

#15,183 in US

#29,080 in the World

San Diego, CA, United States of America

Anaptysbio, Inc.

Forward Citations = 81

19 inventors:

David J King (17 out of 53 patents)

Peter M Bowers (11 out of 11 patents)

Robert A Horlick (10 out of 15 patents)

4. Marilyn Kehry (7 out of 12 patents)

5. Andrew John McKnight (6 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…